DexCom (NASDAQ:DXCM) PT Raised to $189.00

DexCom (NASDAQ:DXCM) had its target price lifted by equities researchers at Raymond James from $172.00 to $189.00 in a research report issued on Thursday, The Fly reports. The firm currently has an “outperform” rating on the medical device company’s stock. Raymond James’ price objective suggests a potential downside of 4.58% from the company’s current price.

DXCM has been the subject of several other reports. Piper Jaffray Companies set a $182.00 price objective on shares of DexCom and gave the company a “buy” rating in a report on Monday, September 23rd. BTIG Research reiterated a “hold” rating on shares of DexCom in a report on Thursday, August 1st. Oppenheimer increased their price objective on shares of DexCom from $167.00 to $180.00 in a report on Thursday, August 1st. Robert W. Baird increased their price objective on shares of DexCom from $195.00 to $240.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Stifel Nicolaus initiated coverage on shares of DexCom in a report on Tuesday, October 22nd. They issued a “buy” rating and a $190.00 price objective for the company. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $190.67.

Shares of DexCom stock traded up $3.38 during trading on Thursday, reaching $198.08. The company had a trading volume of 2,580,200 shares, compared to its average volume of 1,138,483. DexCom has a fifty-two week low of $105.05 and a fifty-two week high of $200.80. The company has a debt-to-equity ratio of 1.56, a quick ratio of 5.64 and a current ratio of 6.05. The company has a market cap of $14.00 billion, a price-to-earnings ratio of 660.27 and a beta of 0.64. The firm’s fifty day moving average is $155.57 and its 200-day moving average is $146.29.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Wednesday, November 6th. The medical device company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.45. The business had revenue of $396.30 million during the quarter, compared to analysts’ expectations of $348.99 million. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The business’s revenue was up 48.6% on a year-over-year basis. During the same period last year, the firm posted $0.17 earnings per share. On average, research analysts anticipate that DexCom will post 0.94 EPS for the current fiscal year.

In related news, CEO Kevin R. Sayer sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $156.12, for a total transaction of $1,561,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Heather S. Ace sold 7,243 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $174.80, for a total transaction of $1,266,076.40. The disclosure for this sale can be found here. Insiders have sold 105,222 shares of company stock valued at $16,407,406 over the last 90 days. 1.80% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the stock. OLD National Bancorp IN boosted its holdings in DexCom by 1.1% during the second quarter. OLD National Bancorp IN now owns 9,838 shares of the medical device company’s stock worth $1,474,000 after buying an additional 108 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in shares of DexCom by 23.6% in the 2nd quarter. Janney Montgomery Scott LLC now owns 12,360 shares of the medical device company’s stock valued at $1,852,000 after acquiring an additional 2,357 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of DexCom by 14.1% in the 2nd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 12,320 shares of the medical device company’s stock valued at $1,846,000 after acquiring an additional 1,519 shares in the last quarter. United Capital Financial Advisers LLC lifted its position in shares of DexCom by 20.6% in the 2nd quarter. United Capital Financial Advisers LLC now owns 3,161 shares of the medical device company’s stock valued at $474,000 after acquiring an additional 539 shares in the last quarter. Finally, MayTech Global Investments LLC lifted its position in shares of DexCom by 2.1% in the 2nd quarter. MayTech Global Investments LLC now owns 45,365 shares of the medical device company’s stock valued at $6,797,000 after acquiring an additional 934 shares in the last quarter. Hedge funds and other institutional investors own 96.19% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Article: Lock-Up Period Expiration

The Fly

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.